A salmonella outbreak tied to imported moringa leaf powder in dietary supplements has now sickened 119 people across 36 states, triggering a chain of recalls from at least three companies and drawing parallel investigations by the FDA and CDC. The contamination has been traced to capsules and powdered greens products sold under multiple brand names, with no deaths reported but hospitalizations confirmed. The widening scope of the recalls, including at least one expansion after a supply-chain review, raises pointed questions about whether a shared overseas processor is the common thread linking products from otherwise unrelated U.S. supplement brands.
Why 119 salmonella cases across 36 states demand attention now
Three separate supplement companies have pulled moringa products from shelves since the FDA opened its outbreak investigation in January 2026. Why Not Natural, a Houston-based company, recalled its Organic Moringa Green Superfood capsules after testing identified contamination in the moringa leaf powder ingredient. Total Nutrition Inc. recalled its TNVitamins and Doctor’s Pride Ultra Potent Complete Green Superfood Moringa Capsules. Superfoods Inc., operating as Live it Up, recalled its Live it Up Super Greens in both Original and Wild Berry varieties. Each recall notice cited the same risk: salmonella contamination found in moringa leaf powder used as an ingredient.
The pattern that stands out is not the number of brands but how the recalls grew. Total Nutrition Inc. initially pulled specific lots, then expanded the recall after further supply-chain review. That language, “further supply chain review,” signals that the company or regulators traced the contamination upstream from the finished capsules to a shared ingredient source. When multiple brands using the same raw material fall in sequence, the problem is less likely to be a single farm or a one-off processing failure. It points instead toward a common supplier or processor handling moringa powder before it reaches U.S. companies for encapsulation and packaging.
The FDA’s CORE/CARA investigation, tracked under CARA ID 1365, identified two salmonella strains in this outbreak: Salmonella Newport and Salmonella Kentucky. Finding two distinct serotypes in the same ingredient stream strengthens the case that contamination occurred at a processing stage where large volumes of moringa from different growing areas were blended or handled together, rather than at a single farm where one strain would typically dominate. The dual-strain finding also complicates traceback work, because investigators must map how each strain moved through the supply chain and into consumer products.
FDA sampling, two salmonella strains, and the recall trail
The FDA’s master outbreak-investigations table lists multiple moringa-related salmonella entries with separate outbreak IDs and status changes, confirming that regulators have been tracking this problem across more than one investigation window. The CARA ID 1365 report, dated February 2026, documents notification dates, sampling counts, and references to FDA-483 issuance, the formal notice that an inspection found significant violations at a facility. That detail is telling: an FDA-483 means inspectors identified specific failures in manufacturing, processing, or holding conditions that could contribute to contamination, such as inadequate cleaning of equipment or improper temperature controls.
The CDC’s consumer advisory, published as part of its outbreak update, tied the illnesses directly to moringa leaf powder in dietary supplements and listed the implicated products alongside distribution details. According to reporting by the Associated Press, the affected products reached major retailers including Sam’s Club, where moringa capsules were sold under the Member’s Mark label. That retail footprint helps explain how 119 confirmed cases spread across 36 states. These were not niche products sold only through specialty health stores or online marketplaces. They sat on shelves at one of the largest warehouse club chains in the country, as well as other outlets and direct-to-consumer channels.
Consumer interviews conducted during the investigation found high exposure rates to moringa supplements among the sick. Many reported taking moringa capsules or powdered greens daily as part of wellness routines, sometimes mixing products from more than one brand. The FDA’s outbreak page and the CDC’s advisory both directed consumers to stop using the recalled products immediately and to report any illness through the FDA’s problem-reporting portal. The recall notices from all three companies instructed buyers to return or discard affected lots and contact the companies for refunds, underscoring that even unopened bottles should not be consumed.
One of the earliest company actions came when Why Not Natural announced it was recalling its capsules because of the contamination risk. That step, followed by the later recalls and the expansion by Total Nutrition Inc., created a recall trail that regulators could compare against illness onset dates and product-distribution records. Matching bar codes, lot numbers, and production dates to patient interviews allowed investigators to narrow the likely contamination window and focus sampling on specific shipments of imported moringa powder.
Unresolved questions about the overseas supply chain
The most significant gap in the public record is the identity of the overseas moringa supplier or processor. None of the FDA recall notices or the CARA report names the foreign facility where the contaminated powder originated. Without that information, consumers have no way to know whether other moringa products on the market, ones not yet recalled, came from the same source. The FDA’s outbreak investigation page does not list a country of origin, and the recall announcements from the three companies describe the moringa only as imported.
The absence of published FDA-483 inspection reports from the foreign facility, despite the CARA document referencing 483 issuance, leaves a hole in the accountability chain. If inspectors found violations serious enough to warrant a 483, the specific findings would reveal whether the problem was inadequate heat treatment, poor sanitation, water contamination, pest intrusion, or something else. That distinction matters because it determines whether the fix is straightforward-such as upgrading a specific step in the kill process-or whether the facility’s entire operation is compromised and requires deeper structural changes or suspension of imports.
No public data confirms how many additional moringa supplement brands may source from the same processor. The dietary supplement industry relies heavily on contract manufacturers and ingredient brokers, meaning a single bulk shipment of moringa powder can be subdivided and resold multiple times before it reaches the companies whose names appear on retail labels. That complexity makes it plausible that more brands used the same contaminated lots without realizing it, particularly if documentation in the supply chain was incomplete or inconsistent.
For regulators, the unanswered question is how far upstream the corrective actions will reach. If the FDA’s investigation ultimately identifies systemic problems at an overseas processor, the agency could impose import alerts, subjecting future shipments of moringa powder from that facility-or even from that region-to detention and testing at the border. Yet until those steps are announced publicly, consumers and smaller supplement brands remain in the dark about which sources are considered high risk.
The outbreak also exposes the limits of current transparency rules around dietary supplements. Unlike conventional foods, supplements operate under a framework that does not require premarket approval, and detailed ingredient sourcing often remains proprietary. That makes it difficult for consumers to assess whether two products that look different on the shelf actually share the same upstream supplier. In the case of the moringa outbreak, three brands with distinct marketing and packaging were linked only after epidemiologists and inspectors connected the dots between illness clusters, lab-confirmed strains, and ingredient records.
Public-health officials stress that most people who contract salmonella recover without treatment, but the pathogen can cause severe illness in young children, older adults, and people with weakened immune systems. The fact that a product marketed for health and wellness became a vehicle for infection underscores why outbreaks like this one draw such close scrutiny. As the FDA and CDC continue their joint investigations, the key issues to watch are whether additional brands are drawn into the recall net, whether the overseas processor is formally identified, and whether the findings prompt broader reforms in how imported botanical ingredients for supplements are vetted and monitored.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
